{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:30:25Z","timestamp":1793611825026,"version":"4.5.0"},"reference-count":59,"publisher":"American Chemical Society (ACS)","issue":"21","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H03825"],"award-info":[{"award-number":["21H03825"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K03471"],"award-info":[{"award-number":["25K03471"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008656","name":"Iketani Science and Technology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008656","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tumor-specific cytotoxic T cells (CTLs) recognize and eliminate tumor cells presenting the tumor-associated antigens on major histocompatibility complex (MHC) class I molecules. However, the efficacy of vaccine-induced CTLs is often limited by the low immunogenicity of self-derived tumor antigens. Because the magnitude of an immune response is closely associated with antigen immunogenicity, strategies that enhance the antigenicity of tumor cells can improve the effectiveness of cancer vaccines. In this study, we prepared a series of conjugates consisting of hyaluronic acid (HA), a tumor-targeting carrier, and the highly immunogenic ovalbumin (OVA)-derived peptide OVA257\u2013264. The peptide was conjugated to amino-modified HA through a disulfide linkage using a cysteine-extended OVA257\u2013264 (C-OVA257\u2013264). We then evaluated whether delivery of C-OVA257\u2013264 could induce presentation of a foreign antigen on MHC class I molecules of B16F10 melanoma cells. Treatment of B16F10 cells with the conjugate HA-C-OVA257\u2013264 efficiently induced presentation of C-OVA257\u2013264 on H-2Kb molecules. Coculture of B16F10 cells treated with HA-C-OVA257\u2013264 and splenocytes containing OVA257\u2013264-specific CTLs resulted in robust interferon gamma production and pronounced CTL-mediated cytotoxicity. Similar antigen results were obtained using C-SARS902\u2013909, a peptide capable of binding H-2Kb and potentially compatible with selected human HLA class I molecules. These findings indicate that foreign antigenic peptides delivered by HA can be presented on MHC class I molecules of tumor cells and subsequently recognized by antigen-specific CTLs. This antigen-replacement strategy represents a promising platform for the development of next-generation cancer vaccines and other antigen-specific immunotherapies.<\/jats:p>","DOI":"10.1021\/acsabm.6c01600","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:01:40Z","timestamp":1790978500000},"page":"10391-10402","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing Tumor Immunogenicity through Hyaluronic Acid-Mediated Delivery of Nonself Antigenic Peptides"],"prefix":"10.1021","volume":"9","author":[{"given":"Aki","family":"Kakinami","sequence":"first","affiliation":[{"name":"The University of Kitakyushu , , 1-1 Hibikino, Wakamatsu-ku , , ,","place":["Kitakyushu, Fukuoka, Japan, 808-0135"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Oitate","sequence":"additional","affiliation":[{"name":"The University of Kitakyushu , , 1-1 Hibikino, Wakamatsu-ku , , ,","place":["Kitakyushu, Fukuoka, Japan, 808-0135"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9832-5070","authenticated-orcid":true,"given":"Shinichi","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"The University of Kitakyushu , , 1-1 Hibikino, Wakamatsu-ku , , ,","place":["Kitakyushu, Fukuoka, Japan, 808-0135"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"2026110201071509000_cit1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.0105-2896.2006.00391.x","article-title":"CD8+ T-cell memory in tumor immunology and immunotherapy","volume":"211","author":"Klebanoff","year":"2006","journal-title":"Immunol Rev"},{"issue":"12","key":"2026110201071509000_cit2","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","article-title":"A guide to antigen processing and presentation","volume":"22","author":"Pishesha","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"2026110201071509000_cit3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev.immunol.20.100201.131730","article-title":"Lymphocyte-mediated cytotoxicity","volume":"20","author":"Russell","year":"2002","journal-title":"Annu. Rev. Immunol."},{"issue":"6","key":"2026110201071509000_cit4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1159\/000512729","article-title":"Antigen-Presenting Cells: Potential of Proven und New Players in Immune Therapies","volume":"47","author":"Eiz-Vesper","year":"2020","journal-title":"Transfus. Med. Hemother."},{"issue":"1","key":"2026110201071509000_cit5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1084\/jem.183.1.87","article-title":"Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines","volume":"183","author":"Zitvogel","year":"1996","journal-title":"J. Exp. Med."},{"issue":"6","key":"2026110201071509000_cit6","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review","volume":"234","author":"Farhood","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"10","key":"2026110201071509000_cit7","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1073\/pnas.0914879107","article-title":"Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens","volume":"107","author":"Jordan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"2026110201071509000_cit8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41587-019-0390-x","article-title":"Peptide-TLR-7\/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens","volume":"38","author":"Lynn","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"2026110201071509000_cit9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/cmi.2012.37","article-title":"A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling","volume":"10","author":"Xie","year":"2013","journal-title":"Cell. Mol. Immunol."},{"issue":"17","key":"2026110201071509000_cit10","doi-asserted-by":"publisher","DOI":"10.3390\/cells12172159","article-title":"Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"key":"2026110201071509000_cit11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103378","article-title":"Therapeutic anti-cancer vaccines: a systematic review of prospective intervention trials for common hematological malignancies","volume":"86","author":"Shah","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"1","key":"2026110201071509000_cit12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.180.1.1","article-title":"Cancer antigens: immune recognition of self and altered self","volume":"180","author":"Houghton","year":"1994","journal-title":"J Exp Med"},{"issue":"1","key":"2026110201071509000_cit13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0092-8674(95)90047-0","article-title":"Induction of anti-self-immunity to cure cancer","volume":"82","author":"Nanda","year":"1995","journal-title":"Cell"},{"issue":"2","key":"2026110201071509000_cit14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41577-023-00911-8","article-title":"A guide to thymic selection of T cells","volume":"24","author":"Ashby","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"2026110201071509000_cit15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/978-0-387-09789-3_9","article-title":"Serial triggering model","volume":"640","author":"Rachmilewitz","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"2026110201071509000_cit16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/imr.12002","article-title":"Structural basis for self-recognition by autoimmune T-cell receptors","volume":"250","author":"Yin","year":"2012","journal-title":"Immunol. Rev."},{"key":"2026110201071509000_cit17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.molimm.2017.12.005","article-title":"The regulatory network behind MHC class I expression","volume":"113","author":"Jongsma","year":"2019","journal-title":"Mol. Immunol."},{"issue":"10","key":"2026110201071509000_cit18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nri1708","article-title":"Regulation of MHC class II gene expression by the class II transactivator","volume":"5","author":"Reith","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"2026110201071509000_cit19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2019.08.006","article-title":"Hyaluronan as tunable drug delivery system","volume":"146","author":"Passi","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"22","key":"2026110201071509000_cit20","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1002\/adhm.201600316","article-title":"Hyaluronic Acid and Its Derivatives in Coating and Delivery Systems: Applications in Tissue Engineering, Regenerative Medicine and Immunomodulation","volume":"5","author":"Knopf-Marques","year":"2016","journal-title":"Adv. Healthcare Mater."},{"key":"2026110201071509000_cit21","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jconrel.2021.07.002","article-title":"Recent advances and prospects of hyaluronan as a multifunctional therapeutic system","volume":"336","author":"Kotla","year":"2021","journal-title":"J. Controlled Release"},{"issue":"17","key":"2026110201071509000_cit22","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1039\/D3BM00439B","article-title":"Modification of the antigenicity of cancer cells by conjugates consisting of hyaluronic acid and foreign antigens","volume":"11","author":"Ogata","year":"2023","journal-title":"Biomater. Sci."},{"key":"2026110201071509000_cit23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.105666","article-title":"Interaction between CD44 and highly condensed hyaluronic acid through crosslinking with proteins","volume":"121","author":"Tsuji","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"1","key":"2026110201071509000_cit24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1152\/physrev.00052.2009","article-title":"Hyaluronan as an immune regulator in human diseases","volume":"91","author":"Jiang","year":"2011","journal-title":"Physiol. Rev."},{"issue":"5","key":"2026110201071509000_cit25","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2174\/156800911795655976","article-title":"CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis","volume":"11","author":"Serafino","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"2026110201071509000_cit26","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2022.830671","article-title":"Chemical Modification of Hyaluronan and Their Biomedical Applications","volume":"10","author":"Hintze","year":"2022","journal-title":"Front. Chem."},{"issue":"7","key":"2026110201071509000_cit27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.stam.2006.05.010","article-title":"Hyaluronan conjugation of antigenic protein to modify immunogenic information","volume":"7","author":"Mochizuki","year":"2006","journal-title":"Sci. Technol. Adv. Mater."},{"issue":"4","key":"2026110201071509000_cit28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1021\/bc970213m","article-title":"Synthesis of novel polyampholyte comb-type copolymers consisting of a poly(L-lysine) backbone and hyaluronic acid side chains for a DNA carrier","volume":"9","author":"Asayama","year":"1998","journal-title":"Bioconjugate Chem."},{"key":"2026110201071509000_cit29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.actbio.2017.11.010","article-title":"Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy","volume":"66","author":"Liu","year":"2018","journal-title":"Acta Biomater."},{"key":"2026110201071509000_cit30","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jconrel.2022.04.023","article-title":"PD-L1 siRNA-hyaluronic acid conjugate for dual-targeted cancer immunotherapy","volume":"346","author":"Kim","year":"2022","journal-title":"J. Controlled Release"},{"key":"2026110201071509000_cit31","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122006","article-title":"Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival","volume":"294","author":"Catania","year":"2023","journal-title":"Biomaterials"},{"key":"2026110201071509000_cit32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jconrel.2014.12.007","article-title":"A polymeric conjugate foreignizing tumor cells for targeted immunotherapy in vivo","volume":"199","author":"Lee","year":"2015","journal-title":"J. Controlled Release"},{"issue":"2-3","key":"2026110201071509000_cit33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.molimm.2009.09.026","article-title":"Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation","volume":"47","author":"Singh","year":"2009","journal-title":"Mol. Immunol."},{"issue":"11","key":"2026110201071509000_cit34","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1021\/acs.bioconjchem.0c00523","article-title":"Immune Responses and Antitumor Effect through Delivering to Antigen Presenting Cells by Optimized Conjugates Consisting of CpG-DNA and Antigenic Peptide","volume":"31","author":"Irie","year":"2020","journal-title":"Bioconjugate Chem."},{"issue":"2","key":"2026110201071509000_cit35","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1021\/acs.bioconjchem.2c00592","article-title":"Tyrosinase-Related Protein2 Peptide with Replacement of N-Terminus Residue by Cysteine Binds to H-2K(b) and Induces Antigen-Specific Cytotoxic T Lymphocytes after Conjugation with CpG-DNA","volume":"34","author":"Irie","year":"2023","journal-title":"Bioconjugate Chem."},{"key":"2026110201071509000_cit36","doi-asserted-by":"publisher","first-page":"D1311","DOI":"10.2741\/A683","article-title":"Getting into the groove: unusual features of peptide binding to MHC class I molecules and implications in vaccine design","volume":"6","author":"Apostolopoulos","year":"2001","journal-title":"Front. Biosci."},{"issue":"7","key":"2026110201071509000_cit37","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic Classification of Cutaneous Melanoma","volume":"161","author":"The Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"issue":"6","key":"2026110201071509000_cit38","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/ijc.35463","article-title":"Global burden of cutaneous melanoma incidence attributable to ultraviolet radiation in 2022","volume":"157","author":"Langselius","year":"2025","journal-title":"Int. J. Cancer"},{"issue":"21","key":"2026110201071509000_cit39","first-page":"4895","article-title":"Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)","volume":"58","author":"Parkhurst","year":"1998","journal-title":"Cancer Res."},{"issue":"8","key":"2026110201071509000_cit40","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.4049\/jimmunol.165.8.4731","article-title":"In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program","volume":"165","author":"Cochlovius","year":"2000","journal-title":"J. Immunol."},{"issue":"26","key":"2026110201071509000_cit41","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"2026110201071509000_cit42","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2026110201071509000_cit43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semcancer.2019.12.005","article-title":"Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies","volume":"65","author":"Ajina","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"14","key":"2026110201071509000_cit44","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1016\/j.biomaterials.2011.01.067","article-title":"Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery","volume":"32","author":"Zhang","year":"2011","journal-title":"Biomaterials"},{"issue":"10","key":"2026110201071509000_cit45","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/nm1001-1159","article-title":"Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay","volume":"7","author":"Becker","year":"2001","journal-title":"Nat. Med."},{"issue":"5072","key":"2026110201071509000_cit46","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1126\/science.1323877","article-title":"Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb","volume":"257","author":"Fremont","year":"1992","journal-title":"Science"},{"issue":"8","key":"2026110201071509000_cit47","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2026110201071509000_cit48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1808146","article-title":"Neoantigen-based cancer vaccines: a mechanistic and clinical review of personalised melanoma immunotherapy","volume":"17","author":"Yu","year":"2026","journal-title":"Front. Immunol."},{"issue":"8","key":"2026110201071509000_cit49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042991","article-title":"Spatio-temporal patterns of pancreatic cancer cells expressing CD44 isoforms on supported membranes displaying hyaluronic acid oligomers arrays","volume":"7","author":"Kaindl","year":"2012","journal-title":"PLoS One"},{"key":"2026110201071509000_cit50","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4103\/jomfp.JOMFP_246_18","article-title":"Structure, function and role of CD44 in neoplasia","volume":"23","author":"Mishra","year":"2019","journal-title":"J. Oral Maxillofac. Pathol."},{"issue":"12","key":"2026110201071509000_cit51","doi-asserted-by":"publisher","DOI":"10.3390\/biom11121850","article-title":"CD44: A multifunctional mediator of cancer progression","volume":"11","author":"Hassn Mesrati","year":"2021","journal-title":"Biomolecules"},{"issue":"24","key":"2026110201071509000_cit52","doi-asserted-by":"publisher","first-page":"7970","DOI":"10.1111\/febs.16179","article-title":"The state of CD44 activation in cancer progression and therapeutic targeting","volume":"289","author":"Guo","year":"2022","journal-title":"FEBS J."},{"key":"2026110201071509000_cit53","doi-asserted-by":"publisher","first-page":"37733","DOI":"10.1074\/jbc.M003030200","article-title":"Identification of hyaluronan receptor for endocytosis (HARE)","volume":"275","author":"Zhou","year":"2000","journal-title":"J. Biol. Chem."},{"key":"2026110201071509000_cit54","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1006\/prep.1998.0971","article-title":"Characterization of a functional hyaluronan-binding domain from the human CD44 molecule expressed in Escherichia Coli","volume":"14","author":"Banerji","year":"1998","journal-title":"Protein Expression Purif."},{"key":"2026110201071509000_cit55","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.actbio.2016.12.026","article-title":"Molecular weight specific impact of soluble and immobilized hyaluronan on CD44 expressing melanoma cells in 3D collagen matrices","volume":"50","author":"Sapudom","year":"2017","journal-title":"Acta Biomater."},{"issue":"4","key":"2026110201071509000_cit56","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040838","article-title":"Hyaluronic acid: known for almost a century, but still in vogue","volume":"14","author":"Lierova","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026110201071509000_cit57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jconrel.2017.08.032","article-title":"A PEGylated hyaluronic acid conjugate for targeted cancer immunotherapy","volume":"267","author":"Shin","year":"2017","journal-title":"J. Controlled Release"},{"issue":"3","key":"2026110201071509000_cit58","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","article-title":"Interferons alpha and beta in cancer: therapeutic opportunities from new insights","volume":"18","author":"Borden","year":"2019","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"1","key":"2026110201071509000_cit59","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13059-021-02357-4","article-title":"Endogenous retroviruses in the origins and treatment of cancer","volume":"22","author":"Jansz","year":"2021","journal-title":"Genome Biol."}],"container-title":["ACS Applied Bio Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsabm.6c01600","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aabmcb\/article-pdf\/9\/21\/10391\/68738531\/mt-2026-016009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aabmcb\/article-pdf\/9\/21\/10391\/68738531\/mt-2026-016009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:10:24Z","timestamp":1793610624000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aabmcb\/article\/9\/21\/10391\/5444138\/Enhancing-Tumor-Immunogenicity-through-Hyaluronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":59,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2026,10,2]]},"published-print":{"date-parts":[[2026,11,2]]}},"URL":"https:\/\/doi.org\/10.1021\/acsabm.6c01600","relation":{},"ISSN":["2576-6422"],"issn-type":[{"value":"2576-6422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]}}}